SCM
PCSA icon

Stonepine Capital Management’s Processa Pharmaceuticals PCSA Stock Holding History

Stonepine Capital Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Hold
55,000
– – 0.06% 83
2026
Q1 		$139K Buy
55,000
+42,677
+346% +$117K 0.06% 76
2025
Q4 		$35.5K Sell
12,323
-28,885
-70% -$202K 0.03% 66
2025
Q3 		$198K Buy
+41,208
New +$218K 0.16% 54

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Stonepine Capital Management's PCSA Position: Q2 2026 in Review

Stonepine Capital Management held its Processa Pharmaceuticals (PCSA) position steady in Q2 2026 at 55,000 shares worth $106K. The position accounts for 0.06% of the portfolio, ranked #83.

Stonepine Capital Management first reported a position in PCSA in Q3 2025 and has held it in 4 quarters since. The position peaked at $198K in Q3 2025. 12 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

  • Stonepine Capital Management held 55,000 shares of Processa Pharmaceuticals worth $106K as of Q2 2026.
  • Stonepine Capital Management left its Processa Pharmaceuticals share count unchanged in Q2 2026.
  • Processa Pharmaceuticals made up 0.06% of Stonepine Capital Management's portfolio in Q2 2026, its #83 holding.
  • Stonepine Capital Management first reported a position in Processa Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Stonepine Capital Management's Processa Pharmaceuticals position peaked at $198K in Q3 2025.
  • 12 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.